Infusion of a single dose of erythropoietin to Prevent Injury in an Ischemia Reperfusion forearm model - A randomised cross-over study to evaluate if infusion of a single dose of EPO protects against ischemia-reperfusion injury in man. - IPIIR

niversity Medical Center Groningen, dept. of Cardiology0 个研究点目标入组 18 人开始时间: 2008年5月29日最近更新: 2021年12月21日

试验速览

暂无简介。

•Healthy volunteers between 18 and 40 years of age.
•Volunteers are not allowed smoking 24 hours before the start of the experiment.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Hypertension (SBP >140 mmHg, DBP >90 mmHg).
•Diabetes Mellitus (DM) (fasting glc >6.9 mmol/l, glc >11.0 mmol/l).
•Hypercholesterolemia.
•Renal dysfunction (eGFR < 60 ml/min, calculated using MDRD formula).
•Any known hypersensitivity/allergic reaction to one of the constituents of Epoetin Alfa.
•A history of use of any form of EPO.
•Any current medication use.
•Cardiovascular disease in medical history.
•Smoking less than 24 hours prior to Epoetin alpha infusion.
•Participation in research in the last 5 years in which any form of radioactivity was used.
•No participation in any research trial in the last 30 days or 5 times the half-life of the used substance.

发起方

niversity Medical Center Groningen, dept. of Cardiology